Ethopropazine	ethopropazine	O	O	OTHERS	I
and	and	O	O	O	O
benztropine	benztropine	O	O	OTHERS	I
in	in	O	O	O	O
neuroleptic-induced	neuroleptic-induced	O	O	O	O
parkinsonism	parkinsonism	O	DISEASE	OTHERS	I
.	.	O	O	O	O

In	in	O	O	O	O
a	a	O	O	O	O
12-week	12-week	O	O	O	O
controlled	controlled	O	O	O	O
study	study	O	O	O	O
ethopropazine	ethopropazine	O	O	OTHERS	I
was	was	O	O	O	O
compared	compared	O	O	O	O
to	to	O	O	O	O
benztropine	benztropine	O	O	OTHERS	I
in	in	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
parkinsonism	parkinsonism	O	DISEASE	OTHERS	I
induced	induced	O	O	O	O
by	by	O	O	O	O
fluphenazine	fluphenazine	CHEMICALS	O	OTHERS	I
enanthate	enanthate	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
60	60	O	O	O	O
schizophrenic	schizophrenic	O	DISEASE	OTHERS	I
outpatients	outpatients	O	O	O	O
.	.	O	O	O	O

Ethopropazine	ethopropazine	O	O	OTHERS	I
and	and	O	O	O	O
benztropine	benztropine	O	O	OTHERS	I
were	were	O	O	O	O
found	found	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
equally	equally	O	O	O	O
effective	effective	O	O	O	O
in	in	O	O	O	O
controlling	controlling	O	O	O	O
parkinsonian	parkinsonian	O	DISEASE	OTHERS	I
symptoms	symptoms	O	O	OTHERS	I
and	and	O	O	O	O
were	were	O	O	O	O
as	as	O	O	O	O
efficacious	efficacious	O	O	O	O
as	as	O	O	O	O
procyclidine	procyclidine	O	O	OTHERS	I
,	,	O	O	O	O
their	their	O	O	O	O
previous	previous	O	O	O	O
antiparkinsonian	antiparkinsonian	O	O	O	O
drug	drug	O	O	O	O
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
benztropine	benztropine	O	O	OTHERS	I
treated	treated	O	O	O	O
patients	patients	O	O	O	O
had	had	O	O	O	O
a	a	O	O	O	O
significant	significant	O	O	O	O
increase	increase	O	O	O	O
in	in	O	O	O	O
tardive	tardive	O	DISEASE	OTHERS	I
dyskinesia	dyskinesia	O	DISEASE	OTHERS	I
compared	compared	O	O	O	O
to	to	O	O	O	O
their	their	O	O	O	O
condition	condition	O	O	O	O
during	during	O	O	O	O
procyclindine	procyclindine	O	O	OTHERS	I
treatment	treatment	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
significantly	significantly	O	O	O	O
more	more	O	O	O	O
anxiety	anxiety	O	DISEASE	OTHERS	I
and	and	O	O	O	O
depression	depression	O	DISEASE	OTHERS	I
than	than	O	O	O	O
ethopropazine	ethopropazine	O	O	OTHERS	I
treated	treated	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
suggests	suggests	O	O	O	O
that	that	O	O	O	O
benztropine	benztropine	O	O	OTHERS	I
is	is	O	O	O	O
not	not	O	O	O	O
the	the	O	O	O	O
anticholinergic	anticholinergic	O	O	O	O
drug	drug	O	O	O	O
of	of	O	O	O	O
choice	choice	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
neuroleptic-induced	neuroleptic-induced	O	O	O	O
parkinsonian	parkinsonian	O	DISEASE	OTHERS	I
symptoms	symptoms	O	O	OTHERS	I
,	,	O	O	O	O
because	because	O	O	O	O
of	of	O	O	O	O
its	its	O	O	O	O
more	more	O	O	O	O
toxic	toxic	O	O	O	O
central	central	O	O	O	O
and	and	O	O	O	O
peripheral	peripheral	O	O	O	O
atropinic	atropinic	O	O	O	O
effect	effect	O	O	O	O
.	.	O	O	O	O

